Kanesvaran, Ravindran and Porta, C. and Wong, A. and Powles, T. and Ng, Q. S. and Schmidinger, M. and Ye, D. and Malhotra, H. and Miura, Y. and Lee, J. L. and Chong, F. L. T. and Pu, Y-S and Yen, C-C and Saad, Marniza and Lee, H. J. and Kitamura, H. and Bhattacharyya, G. S. and Curigliano, G. and Poon, E. and Choo, S. P. and Peters, S. and Lim, E. and Yoshino, T. and Pentheroudakis, G. (2021) Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO Open, 6 (6). ISSN 2059-7029, DOI https://doi.org/10.1016/j.esmoop.2021.100304.
Full text not available from this repository.Abstract
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of renal cell carcinoma was published in 2019 with an update planned for 2021. It was therefore decided by both the ESMO and the Singapore Society of Oncology (SSO) to convene a special, virtual guidelines meeting in May 2021 to adapt the ESMO 2019 guidelines to take into account the ethnic differences associated with the treatment of renal cell carcinomas in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with renal cell carcinoma representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate.
| Item Type: | Article |
|---|---|
| Funders: | ESMO Singapore Office, EUSA, MSD Eisai, Merck Biopharma, ONO, RTP, Scientific and Medical Division of ESMO, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Astellas Pharma US, AstraZeneca, Bayer, GlaxoSmithKline, Johnson and Johnson, Merck, Novartis, Roche, Sanofi, Meso Scale Diagnostics, Boehringer Ingelheim, Takeda Pharmaceutical Company, Janssen Pharmaceuticals, Merck Sharp and Dohme, Exelixis, Daiichi-Sankyo, Eisai, European Society for Medical Oncology, Ipsen |
| Uncontrolled Keywords: | ESMO; Guidelines; Kidney cancer; Pan-Asian; Renal cell carcinoma treatment |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Faculty of Medicine > Clinical Oncology Department Universiti Malaya Medical Centre (UMMC) |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 20 Oct 2023 05:27 |
| Last Modified: | 20 Oct 2023 05:27 |
| URI: | http://eprints.um.edu.my/id/eprint/35287 |
Actions (login required)
 |
View Item |
